Hiroko Hayama Dodge, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alzheimer Disease | 52 | 2024 | 8547 | 2.760 |
Why?
|
| Dementia | 33 | 2024 | 2649 | 2.060 |
Why?
|
| Cognition Disorders | 29 | 2018 | 3976 | 1.810 |
Why?
|
| Cognition | 23 | 2024 | 6957 | 1.790 |
Why?
|
| Aging | 30 | 2024 | 8651 | 1.650 |
Why?
|
| Neuropsychological Tests | 45 | 2024 | 7021 | 1.590 |
Why?
|
| Dementia, Vascular | 2 | 2023 | 123 | 1.390 |
Why?
|
| Aged, 80 and over | 103 | 2024 | 58995 | 1.100 |
Why?
|
| Activities of Daily Living | 20 | 2022 | 2417 | 1.020 |
Why?
|
| Japan | 11 | 2020 | 1369 | 0.900 |
Why?
|
| Memory, Short-Term | 3 | 2020 | 978 | 0.890 |
Why?
|
| Mental Status Schedule | 10 | 2016 | 314 | 0.870 |
Why?
|
| Social Isolation | 3 | 2023 | 362 | 0.780 |
Why?
|
| Cerebrovascular Disorders | 4 | 2022 | 1501 | 0.760 |
Why?
|
| Aged | 112 | 2024 | 169152 | 0.670 |
Why?
|
| Executive Function | 6 | 2024 | 1374 | 0.670 |
Why?
|
| Pennsylvania | 20 | 2023 | 615 | 0.660 |
Why?
|
| Fatty Acids, Omega-3 | 6 | 2024 | 1387 | 0.630 |
Why?
|
| Lewy Body Disease | 1 | 2020 | 252 | 0.590 |
Why?
|
| Brain | 22 | 2024 | 26951 | 0.560 |
Why?
|
| Cohort Effect | 1 | 2016 | 39 | 0.560 |
Why?
|
| Disease Progression | 18 | 2024 | 13502 | 0.550 |
Why?
|
| Personality | 1 | 2020 | 552 | 0.550 |
Why?
|
| Oregon | 8 | 2021 | 148 | 0.550 |
Why?
|
| Amyloid beta-Peptides | 6 | 2024 | 3832 | 0.540 |
Why?
|
| Waist Circumference | 1 | 2020 | 926 | 0.520 |
Why?
|
| Speech | 2 | 2024 | 550 | 0.510 |
Why?
|
| Natural Language Processing | 1 | 2024 | 1135 | 0.500 |
Why?
|
| Mood Disorders | 1 | 2021 | 1124 | 0.490 |
Why?
|
| Monitoring, Ambulatory | 2 | 2015 | 353 | 0.480 |
Why?
|
| Microcomputers | 1 | 2014 | 141 | 0.470 |
Why?
|
| Male | 117 | 2024 | 359744 | 0.470 |
Why?
|
| Independent Living | 6 | 2022 | 570 | 0.470 |
Why?
|
| Attitude to Computers | 1 | 2014 | 195 | 0.450 |
Why?
|
| Geriatric Assessment | 14 | 2019 | 1405 | 0.450 |
Why?
|
| Female | 117 | 2024 | 391270 | 0.430 |
Why?
|
| Social Behavior | 3 | 2015 | 1131 | 0.420 |
Why?
|
| Research Subjects | 1 | 2014 | 249 | 0.420 |
Why?
|
| Therapy, Computer-Assisted | 1 | 2014 | 267 | 0.420 |
Why?
|
| Humans | 150 | 2024 | 760621 | 0.410 |
Why?
|
| Computers | 4 | 2017 | 595 | 0.410 |
Why?
|
| Longitudinal Studies | 27 | 2021 | 14495 | 0.400 |
Why?
|
| Cognitive Dissonance | 1 | 2011 | 14 | 0.400 |
Why?
|
| Interview, Psychological | 1 | 2015 | 810 | 0.390 |
Why?
|
| Walking | 3 | 2014 | 1189 | 0.370 |
Why?
|
| Cross-Cultural Comparison | 4 | 2010 | 633 | 0.360 |
Why?
|
| Risk Reduction Behavior | 5 | 2021 | 1109 | 0.360 |
Why?
|
| Plaque, Amyloid | 5 | 2024 | 758 | 0.360 |
Why?
|
| Memory | 4 | 2017 | 2179 | 0.350 |
Why?
|
| Interpersonal Relations | 3 | 2014 | 1428 | 0.340 |
Why?
|
| Gait | 2 | 2012 | 812 | 0.340 |
Why?
|
| Terminally Ill | 1 | 2012 | 240 | 0.340 |
Why?
|
| Neurofibrillary Tangles | 5 | 2023 | 457 | 0.330 |
Why?
|
| Attention | 1 | 2020 | 2387 | 0.330 |
Why?
|
| Clinical Trials as Topic | 3 | 2024 | 8056 | 0.320 |
Why?
|
| Ginkgolides | 1 | 2008 | 7 | 0.310 |
Why?
|
| Educational Status | 9 | 2023 | 2515 | 0.310 |
Why?
|
| Lipoproteins, HDL | 1 | 2013 | 667 | 0.310 |
Why?
|
| Accidental Falls | 4 | 2020 | 1056 | 0.290 |
Why?
|
| Seizures | 1 | 2020 | 2917 | 0.290 |
Why?
|
| Micronutrients | 1 | 2010 | 381 | 0.290 |
Why?
|
| Leisure Activities | 1 | 2008 | 306 | 0.280 |
Why?
|
| Behavior Therapy | 2 | 2024 | 868 | 0.280 |
Why?
|
| Patient Selection | 2 | 2014 | 4283 | 0.270 |
Why?
|
| Telemedicine | 2 | 2021 | 3018 | 0.270 |
Why?
|
| Drugs, Chinese Herbal | 1 | 2008 | 151 | 0.270 |
Why?
|
| Alcohol-Induced Disorders, Nervous System | 1 | 2005 | 13 | 0.260 |
Why?
|
| Communication | 1 | 2020 | 3849 | 0.260 |
Why?
|
| Logistic Models | 11 | 2019 | 13314 | 0.260 |
Why?
|
| Social Support | 3 | 2013 | 2145 | 0.260 |
Why?
|
| Rural Population | 13 | 2006 | 2268 | 0.250 |
Why?
|
| Psychomotor Performance | 5 | 2020 | 1878 | 0.250 |
Why?
|
| Self Disclosure | 1 | 2006 | 249 | 0.250 |
Why?
|
| Triglycerides | 1 | 2013 | 2476 | 0.240 |
Why?
|
| Models, Statistical | 2 | 2018 | 5075 | 0.240 |
Why?
|
| Disabled Persons | 3 | 2005 | 1223 | 0.240 |
Why?
|
| Cohort Studies | 31 | 2020 | 41335 | 0.230 |
Why?
|
| Physicians, Family | 1 | 2006 | 349 | 0.230 |
Why?
|
| Risk Factors | 26 | 2023 | 74359 | 0.230 |
Why?
|
| Linguistics | 1 | 2024 | 106 | 0.220 |
Why?
|
| Diagnosis, Computer-Assisted | 3 | 2020 | 707 | 0.220 |
Why?
|
| Asia | 2 | 2023 | 620 | 0.220 |
Why?
|
| Cholesterol, LDL | 1 | 2013 | 2420 | 0.220 |
Why?
|
| Memory Disorders | 6 | 2017 | 1197 | 0.210 |
Why?
|
| Databases, Factual | 6 | 2020 | 8035 | 0.210 |
Why?
|
| Prospective Studies | 21 | 2020 | 54303 | 0.210 |
Why?
|
| Follow-Up Studies | 16 | 2017 | 39261 | 0.210 |
Why?
|
| Long-Term Care | 2 | 2023 | 632 | 0.200 |
Why?
|
| Internet | 3 | 2024 | 3078 | 0.200 |
Why?
|
| Loneliness | 3 | 2023 | 197 | 0.200 |
Why?
|
| Magnetic Resonance Imaging | 19 | 2024 | 36290 | 0.200 |
Why?
|
| Cerebrovascular Circulation | 3 | 2018 | 2733 | 0.200 |
Why?
|
| Medicaid | 3 | 2024 | 2815 | 0.200 |
Why?
|
| Nerve Fibers, Myelinated | 3 | 2013 | 952 | 0.190 |
Why?
|
| Cerebral Cortex | 1 | 2018 | 5761 | 0.190 |
Why?
|
| Amnesia | 1 | 2023 | 255 | 0.190 |
Why?
|
| Medical Records | 2 | 2006 | 1407 | 0.190 |
Why?
|
| Data Collection | 6 | 2018 | 3315 | 0.190 |
Why?
|
| Michigan | 1 | 2021 | 342 | 0.190 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2017 | 3986 | 0.180 |
Why?
|
| Sex Factors | 9 | 2020 | 10547 | 0.180 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2024 | 791 | 0.170 |
Why?
|
| Single-Blind Method | 1 | 2024 | 1578 | 0.170 |
Why?
|
| Apolipoproteins E | 4 | 2016 | 1436 | 0.170 |
Why?
|
| Writing | 1 | 2021 | 199 | 0.170 |
Why?
|
| Oxylipins | 1 | 2020 | 52 | 0.170 |
Why?
|
| Speech Recognition Software | 1 | 2020 | 74 | 0.170 |
Why?
|
| Home Care Services | 2 | 2023 | 654 | 0.170 |
Why?
|
| Consensus | 3 | 2024 | 3113 | 0.160 |
Why?
|
| Nursing Homes | 2 | 2023 | 1082 | 0.160 |
Why?
|
| Medicare Part C | 1 | 2024 | 322 | 0.160 |
Why?
|
| Sensitivity and Specificity | 6 | 2023 | 14660 | 0.160 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2020 | 227 | 0.150 |
Why?
|
| Telephone | 1 | 2021 | 624 | 0.150 |
Why?
|
| Cerebrum | 1 | 2019 | 132 | 0.150 |
Why?
|
| Metric System | 1 | 2017 | 2 | 0.140 |
Why?
|
| Autopsy | 5 | 2024 | 1007 | 0.140 |
Why?
|
| Health Services | 2 | 1999 | 753 | 0.140 |
Why?
|
| Arteriolosclerosis | 1 | 2017 | 21 | 0.140 |
Why?
|
| Depression | 8 | 2019 | 8044 | 0.140 |
Why?
|
| Life Expectancy | 2 | 2005 | 1248 | 0.140 |
Why?
|
| Age Factors | 13 | 2016 | 18416 | 0.140 |
Why?
|
| Online Systems | 1 | 2017 | 181 | 0.140 |
Why?
|
| Intracranial Arteriosclerosis | 1 | 2017 | 137 | 0.130 |
Why?
|
| Sample Size | 2 | 2015 | 840 | 0.130 |
Why?
|
| Social Mobility | 1 | 1995 | 31 | 0.130 |
Why?
|
| Videoconferencing | 1 | 2017 | 203 | 0.120 |
Why?
|
| Widowhood | 1 | 1995 | 51 | 0.120 |
Why?
|
| International Cooperation | 2 | 2017 | 1433 | 0.120 |
Why?
|
| Copper | 1 | 2018 | 368 | 0.120 |
Why?
|
| Pilot Projects | 5 | 2014 | 8555 | 0.120 |
Why?
|
| Hippocampus | 5 | 2016 | 3738 | 0.120 |
Why?
|
| Self Efficacy | 2 | 2023 | 630 | 0.120 |
Why?
|
| Biomedical Research | 3 | 2020 | 3426 | 0.120 |
Why?
|
| Arachidonic Acid | 1 | 2016 | 433 | 0.120 |
Why?
|
| Cerebral Ventricles | 4 | 2022 | 542 | 0.110 |
Why?
|
| Frail Elderly | 1 | 2019 | 752 | 0.110 |
Why?
|
| Thioctic Acid | 1 | 2014 | 28 | 0.110 |
Why?
|
| United States | 19 | 2024 | 72461 | 0.110 |
Why?
|
| Blood Chemical Analysis | 1 | 2016 | 437 | 0.110 |
Why?
|
| Proportional Hazards Models | 6 | 2016 | 12531 | 0.110 |
Why?
|
| Chi-Square Distribution | 4 | 2013 | 3465 | 0.110 |
Why?
|
| Epidemiologic Studies | 3 | 2003 | 670 | 0.110 |
Why?
|
| Cross-Sectional Studies | 14 | 2020 | 25942 | 0.110 |
Why?
|
| Positron-Emission Tomography | 2 | 2024 | 6465 | 0.110 |
Why?
|
| Language | 4 | 2024 | 1533 | 0.110 |
Why?
|
| Counseling | 1 | 2021 | 1548 | 0.110 |
Why?
|
| Incidence | 7 | 2019 | 21392 | 0.110 |
Why?
|
| Tauopathies | 1 | 2017 | 317 | 0.110 |
Why?
|
| Caregivers | 3 | 2017 | 2224 | 0.110 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 2018 | 8950 | 0.110 |
Why?
|
| Social Identification | 1 | 2013 | 106 | 0.110 |
Why?
|
| Alcohol Drinking | 1 | 2005 | 4013 | 0.100 |
Why?
|
| Anomie | 1 | 1992 | 9 | 0.100 |
Why?
|
| Women's Rights | 1 | 1992 | 65 | 0.100 |
Why?
|
| Automobile Driving | 1 | 2017 | 438 | 0.100 |
Why?
|
| Asymptomatic Diseases | 1 | 2015 | 587 | 0.100 |
Why?
|
| Emotions | 1 | 2023 | 2734 | 0.100 |
Why?
|
| Regression Analysis | 3 | 2018 | 6360 | 0.100 |
Why?
|
| Neuroprotective Agents | 2 | 2008 | 961 | 0.090 |
Why?
|
| Adaptation, Psychological | 2 | 2023 | 2628 | 0.090 |
Why?
|
| Demography | 3 | 2011 | 1650 | 0.090 |
Why?
|
| Organ Size | 5 | 2017 | 2254 | 0.090 |
Why?
|
| Medical Informatics | 1 | 2018 | 732 | 0.090 |
Why?
|
| Medicare | 3 | 2024 | 6786 | 0.090 |
Why?
|
| Serial Learning | 1 | 2010 | 41 | 0.090 |
Why?
|
| Spin Labels | 3 | 2018 | 336 | 0.090 |
Why?
|
| gamma-Tocopherol | 1 | 2010 | 30 | 0.090 |
Why?
|
| Databases as Topic | 1 | 2012 | 474 | 0.090 |
Why?
|
| Pattern Recognition, Automated | 1 | 2017 | 994 | 0.090 |
Why?
|
| Depressive Disorder | 2 | 2019 | 3726 | 0.090 |
Why?
|
| Postural Balance | 2 | 2011 | 617 | 0.090 |
Why?
|
| Affect | 2 | 2017 | 1480 | 0.090 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2024 | 3164 | 0.090 |
Why?
|
| alpha-Tocopherol | 1 | 2010 | 126 | 0.090 |
Why?
|
| Health Services Research | 1 | 2017 | 1810 | 0.090 |
Why?
|
| ROC Curve | 3 | 2018 | 3568 | 0.090 |
Why?
|
| Artificial Intelligence | 2 | 2024 | 2557 | 0.080 |
Why?
|
| Physical Endurance | 1 | 2011 | 363 | 0.080 |
Why?
|
| Middle Aged | 24 | 2023 | 220352 | 0.080 |
Why?
|
| India | 8 | 2004 | 2336 | 0.080 |
Why?
|
| Severity of Illness Index | 7 | 2017 | 15840 | 0.080 |
Why?
|
| Models, Neurological | 1 | 2016 | 1758 | 0.080 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2010 | 238 | 0.080 |
Why?
|
| Internationality | 1 | 2013 | 1004 | 0.080 |
Why?
|
| Peptide Fragments | 2 | 2012 | 5125 | 0.070 |
Why?
|
| Interleukin-6 | 1 | 2018 | 3215 | 0.070 |
Why?
|
| Parietal Lobe | 1 | 2012 | 850 | 0.070 |
Why?
|
| Tissue Donors | 1 | 2017 | 2313 | 0.070 |
Why?
|
| Vitamin B 12 | 1 | 2010 | 522 | 0.070 |
Why?
|
| Homocysteine | 1 | 2010 | 640 | 0.070 |
Why?
|
| Nootropic Agents | 1 | 2008 | 157 | 0.070 |
Why?
|
| Odds Ratio | 4 | 2014 | 9716 | 0.070 |
Why?
|
| Equipment Design | 1 | 2014 | 3520 | 0.070 |
Why?
|
| Community Health Services | 2 | 2023 | 654 | 0.070 |
Why?
|
| Registries | 2 | 2003 | 8469 | 0.070 |
Why?
|
| Psychiatric Status Rating Scales | 4 | 2017 | 6015 | 0.070 |
Why?
|
| Self Report | 2 | 2017 | 3711 | 0.070 |
Why?
|
| Monitoring, Physiologic | 1 | 2014 | 1784 | 0.070 |
Why?
|
| Alcohol Amnestic Disorder | 1 | 2005 | 35 | 0.070 |
Why?
|
| Gender Identity | 1 | 1992 | 698 | 0.070 |
Why?
|
| Potassium | 1 | 2010 | 1313 | 0.070 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2018 | 2782 | 0.070 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2014 | 2007 | 0.060 |
Why?
|
| Ascorbic Acid | 1 | 2009 | 655 | 0.060 |
Why?
|
| Brain Chemistry | 1 | 2009 | 959 | 0.060 |
Why?
|
| Sampling Studies | 3 | 2006 | 613 | 0.060 |
Why?
|
| Research | 1 | 2013 | 1974 | 0.060 |
Why?
|
| Sodium | 1 | 2010 | 1594 | 0.060 |
Why?
|
| Psychometrics | 3 | 2011 | 3051 | 0.060 |
Why?
|
| Risk | 1 | 2016 | 9631 | 0.060 |
Why?
|
| Mental Recall | 1 | 2010 | 1206 | 0.060 |
Why?
|
| Retrospective Studies | 7 | 2018 | 80372 | 0.060 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2011 | 1489 | 0.060 |
Why?
|
| Institutionalization | 1 | 2004 | 105 | 0.060 |
Why?
|
| Hospitalization | 1 | 2023 | 10790 | 0.060 |
Why?
|
| Folic Acid | 1 | 2010 | 1309 | 0.060 |
Why?
|
| Placebos | 1 | 2008 | 1668 | 0.050 |
Why?
|
| Poverty | 1 | 1995 | 2695 | 0.050 |
Why?
|
| Aquaporins | 1 | 2024 | 174 | 0.050 |
Why?
|
| Nutritional Status | 1 | 2011 | 1607 | 0.050 |
Why?
|
| Double-Blind Method | 3 | 2019 | 12427 | 0.050 |
Why?
|
| Diphenhydramine | 1 | 2003 | 63 | 0.050 |
Why?
|
| Computer Simulation | 1 | 2016 | 6218 | 0.050 |
Why?
|
| Healthcare Disparities | 1 | 2018 | 3388 | 0.050 |
Why?
|
| Prevalence | 4 | 2015 | 15687 | 0.050 |
Why?
|
| Socioeconomic Factors | 5 | 2008 | 7806 | 0.050 |
Why?
|
| Residence Characteristics | 3 | 2014 | 2062 | 0.050 |
Why?
|
| Health Status | 2 | 2006 | 4081 | 0.050 |
Why?
|
| Cholinergic Antagonists | 1 | 2003 | 164 | 0.050 |
Why?
|
| tau Proteins | 1 | 2012 | 2085 | 0.050 |
Why?
|
| Body Mass Index | 1 | 2020 | 12914 | 0.050 |
Why?
|
| Mass Screening | 4 | 2020 | 5423 | 0.050 |
Why?
|
| Pandemics | 1 | 2021 | 8624 | 0.050 |
Why?
|
| Reproducibility of Results | 4 | 2017 | 20080 | 0.050 |
Why?
|
| Vision, Ocular | 1 | 2024 | 454 | 0.050 |
Why?
|
| Computational Biology | 2 | 2024 | 3505 | 0.050 |
Why?
|
| Reference Values | 2 | 2006 | 4925 | 0.050 |
Why?
|
| Comorbidity | 3 | 2011 | 10551 | 0.050 |
Why?
|
| Europe | 2 | 2020 | 3441 | 0.050 |
Why?
|
| Antioxidants | 1 | 2009 | 1667 | 0.050 |
Why?
|
| Delphi Technique | 1 | 2024 | 829 | 0.050 |
Why?
|
| Confidence Intervals | 4 | 2011 | 2932 | 0.040 |
Why?
|
| Suicide | 1 | 1992 | 1599 | 0.040 |
Why?
|
| Prognosis | 3 | 2018 | 29658 | 0.040 |
Why?
|
| Eligibility Determination | 1 | 2024 | 421 | 0.040 |
Why?
|
| Risk Assessment | 3 | 2019 | 24123 | 0.040 |
Why?
|
| Tape Recording | 1 | 2020 | 75 | 0.040 |
Why?
|
| Gambling | 1 | 2004 | 258 | 0.040 |
Why?
|
| Ethics Committees, Research | 1 | 2021 | 196 | 0.040 |
Why?
|
| Technology | 1 | 2022 | 291 | 0.040 |
Why?
|
| Vascular Diseases | 1 | 2008 | 1182 | 0.040 |
Why?
|
| Trail Making Test | 1 | 2020 | 57 | 0.040 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2024 | 613 | 0.040 |
Why?
|
| Polymorphism, Genetic | 2 | 2001 | 4291 | 0.040 |
Why?
|
| Hypertension | 1 | 2020 | 8594 | 0.040 |
Why?
|
| Time Factors | 5 | 2019 | 40165 | 0.040 |
Why?
|
| Causality | 1 | 2005 | 1242 | 0.040 |
Why?
|
| Early Diagnosis | 2 | 2016 | 1180 | 0.040 |
Why?
|
| Developing Countries | 2 | 2002 | 2868 | 0.040 |
Why?
|
| Rural Health Services | 1 | 2003 | 381 | 0.040 |
Why?
|
| Inflammation | 1 | 2019 | 10756 | 0.040 |
Why?
|
| Music Therapy | 1 | 2020 | 110 | 0.040 |
Why?
|
| Personal Satisfaction | 1 | 2023 | 643 | 0.040 |
Why?
|
| Aquatic Organisms | 1 | 2019 | 42 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2006 | 2435 | 0.040 |
Why?
|
| Linear Models | 3 | 2016 | 5877 | 0.040 |
Why?
|
| Myelin Sheath | 1 | 2022 | 652 | 0.040 |
Why?
|
| Statistics, Nonparametric | 2 | 2017 | 2852 | 0.040 |
Why?
|
| Research Design | 3 | 2024 | 6180 | 0.040 |
Why?
|
| Hemoglobins | 1 | 2004 | 1521 | 0.040 |
Why?
|
| Behavior, Addictive | 1 | 2004 | 462 | 0.040 |
Why?
|
| Predictive Value of Tests | 5 | 2011 | 15289 | 0.040 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2008 | 2282 | 0.040 |
Why?
|
| Hypolipidemic Agents | 1 | 2002 | 626 | 0.040 |
Why?
|
| Normal Distribution | 1 | 2018 | 273 | 0.040 |
Why?
|
| Secondary Prevention | 1 | 2024 | 1548 | 0.040 |
Why?
|
| Anxiety | 1 | 2012 | 4538 | 0.040 |
Why?
|
| Docosahexaenoic Acids | 1 | 2024 | 912 | 0.040 |
Why?
|
| Meditation | 1 | 2020 | 251 | 0.040 |
Why?
|
| Hypotension | 1 | 2003 | 883 | 0.040 |
Why?
|
| Diabetes Mellitus | 1 | 2016 | 5889 | 0.040 |
Why?
|
| Mortality | 2 | 1998 | 2916 | 0.030 |
Why?
|
| Drug Utilization | 1 | 2003 | 1195 | 0.030 |
Why?
|
| Hypothyroidism | 1 | 2001 | 665 | 0.030 |
Why?
|
| Diffusion Tensor Imaging | 2 | 2018 | 2385 | 0.030 |
Why?
|
| Case-Control Studies | 3 | 2010 | 22053 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2013 | 10344 | 0.030 |
Why?
|
| Cerebral Hemorrhage | 1 | 2008 | 2660 | 0.030 |
Why?
|
| Astrocytes | 1 | 2024 | 1338 | 0.030 |
Why?
|
| North America | 1 | 2020 | 1284 | 0.030 |
Why?
|
| Exercise | 2 | 2020 | 5787 | 0.030 |
Why?
|
| Disclosure | 1 | 2021 | 738 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2018 | 940 | 0.030 |
Why?
|
| Social Security | 1 | 1995 | 101 | 0.030 |
Why?
|
| Hypnotics and Sedatives | 1 | 2003 | 1178 | 0.030 |
Why?
|
| Health Priorities | 1 | 2017 | 374 | 0.030 |
Why?
|
| F2-Isoprostanes | 1 | 2014 | 35 | 0.030 |
Why?
|
| Data Interpretation, Statistical | 2 | 2009 | 2696 | 0.030 |
Why?
|
| Brain Infarction | 1 | 2016 | 292 | 0.030 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2003 | 1079 | 0.030 |
Why?
|
| Obesity | 1 | 2016 | 12922 | 0.030 |
Why?
|
| Head | 1 | 1999 | 922 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 10827 | 0.030 |
Why?
|
| Random Allocation | 1 | 1998 | 2394 | 0.030 |
Why?
|
| Social Environment | 2 | 2004 | 1022 | 0.030 |
Why?
|
| Lewy Bodies | 1 | 2013 | 144 | 0.030 |
Why?
|
| Motor Activity | 2 | 2014 | 2687 | 0.030 |
Why?
|
| Adult | 5 | 2020 | 219994 | 0.020 |
Why?
|
| Australia | 1 | 2015 | 1289 | 0.020 |
Why?
|
| Motivation | 1 | 2021 | 1993 | 0.020 |
Why?
|
| Apolipoprotein E3 | 1 | 2011 | 107 | 0.020 |
Why?
|
| Health Services Needs and Demand | 1 | 1999 | 1399 | 0.020 |
Why?
|
| Analysis of Variance | 2 | 2014 | 6238 | 0.020 |
Why?
|
| Functional Laterality | 1 | 2017 | 2253 | 0.020 |
Why?
|
| Education | 2 | 2004 | 534 | 0.020 |
Why?
|
| Cerebrospinal Fluid | 1 | 2012 | 544 | 0.020 |
Why?
|
| Frontal Lobe | 1 | 2016 | 1420 | 0.020 |
Why?
|
| Diabetes Complications | 1 | 2016 | 1341 | 0.020 |
Why?
|
| Forecasting | 1 | 1998 | 2932 | 0.020 |
Why?
|
| Verbal Learning | 1 | 2010 | 462 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2015 | 1500 | 0.020 |
Why?
|
| Visual Perception | 1 | 2017 | 1374 | 0.020 |
Why?
|
| Temporal Lobe | 1 | 2016 | 1688 | 0.020 |
Why?
|
| Depressive Disorder, Major | 1 | 2006 | 4744 | 0.020 |
Why?
|
| Atrophy | 1 | 2013 | 1627 | 0.020 |
Why?
|
| Cause of Death | 1 | 1998 | 3725 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2003 | 8525 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2002 | 9287 | 0.020 |
Why?
|
| Sex Distribution | 2 | 2004 | 2295 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2017 | 5201 | 0.020 |
Why?
|
| Income | 1 | 1995 | 1875 | 0.020 |
Why?
|
| Multivariate Analysis | 2 | 2016 | 12159 | 0.020 |
Why?
|
| Family Characteristics | 1 | 2011 | 1001 | 0.020 |
Why?
|
| Algorithms | 2 | 2018 | 13981 | 0.020 |
Why?
|
| Mental Health | 1 | 2019 | 3213 | 0.020 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2008 | 370 | 0.020 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2018 | 3340 | 0.020 |
Why?
|
| Apolipoprotein E4 | 1 | 2009 | 707 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 1998 | 5508 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2020 | 12965 | 0.010 |
Why?
|
| Parkinson Disease | 1 | 2018 | 2859 | 0.010 |
Why?
|
| Acetaminophen | 1 | 2008 | 553 | 0.010 |
Why?
|
| Emergency Service, Hospital | 1 | 2023 | 7818 | 0.010 |
Why?
|
| Intelligence Tests | 1 | 2004 | 500 | 0.010 |
Why?
|
| Vitamins | 1 | 2011 | 1634 | 0.010 |
Why?
|
| Treatment Outcome | 2 | 2008 | 65017 | 0.010 |
Why?
|
| Radioligand Assay | 1 | 2003 | 366 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2011 | 6068 | 0.010 |
Why?
|
| Blood-Brain Barrier | 1 | 2009 | 1019 | 0.010 |
Why?
|
| Sick Role | 1 | 2002 | 230 | 0.010 |
Why?
|
| Stroke | 1 | 2004 | 9962 | 0.010 |
Why?
|
| Phenotype | 1 | 2018 | 16546 | 0.010 |
Why?
|
| Vocabulary | 1 | 2001 | 165 | 0.010 |
Why?
|
| Factor Analysis, Statistical | 1 | 2003 | 998 | 0.010 |
Why?
|
| Circadian Rhythm | 1 | 2011 | 2571 | 0.010 |
Why?
|
| Automation | 1 | 2002 | 580 | 0.010 |
Why?
|
| Quality Control | 1 | 2002 | 828 | 0.010 |
Why?
|
| Thyrotropin | 1 | 2001 | 832 | 0.010 |
Why?
|
| Thyroxine | 1 | 2001 | 667 | 0.010 |
Why?
|
| Age of Onset | 1 | 2005 | 3301 | 0.010 |
Why?
|
| Reading | 1 | 2001 | 529 | 0.010 |
Why?
|
| Health Services for the Aged | 1 | 1999 | 259 | 0.010 |
Why?
|
| Aspirin | 1 | 2008 | 3364 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2002 | 2362 | 0.010 |
Why?
|
| Self Concept | 1 | 2001 | 1039 | 0.010 |
Why?
|
| Age Distribution | 1 | 2001 | 2893 | 0.010 |
Why?
|
| Attitude to Health | 1 | 2004 | 2029 | 0.010 |
Why?
|
| Drug Prescriptions | 1 | 2004 | 1673 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2001 | 3615 | 0.010 |
Why?
|
| Antidepressive Agents | 1 | 2006 | 2890 | 0.010 |
Why?
|
| Diet | 1 | 2011 | 8010 | 0.010 |
Why?
|
| Population Surveillance | 1 | 2003 | 2608 | 0.010 |
Why?
|
| Social Class | 1 | 2001 | 2005 | 0.010 |
Why?
|
| HIV Infections | 1 | 2017 | 17165 | 0.010 |
Why?
|
| Survival Rate | 1 | 2005 | 12808 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2002 | 10182 | 0.010 |
Why?
|
| Cost of Illness | 1 | 1999 | 1940 | 0.010 |
Why?
|
| Thyroid Neoplasms | 1 | 2001 | 2332 | 0.000 |
Why?
|
| Animals | 1 | 2016 | 167963 | 0.000 |
Why?
|
| Quality of Life | 1 | 2004 | 13308 | 0.000 |
Why?
|
| Adolescent | 1 | 2008 | 87810 | 0.000 |
Why?
|